Moderna reports vaccine remains highly effective through six months
Moderna Inc. today announced during an investors report that its COVID-19 vaccine remains 93% effective through the first six months following a full dosing regimen.
Moderna also reported that, in its effort to earn full Food and Drug Administration approval for the vaccine, it initiated the rolling submission process for a Biologics License Application for the current vaccine in the U.S., a process it expects to complete its submission in August. Moderna also has completed enrollment for a phase 1 clinical trial of a next-generation COVID-19 vaccine that will be refrigerator-stable.
Related News Articles
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…